Adverse drug reaction reporting by hospital pharmacists in Saudi Arabia

Saudi Pharmaceutical Journal

Volumn 17, Issue 1, 2009, Pages 95-105

  Al Sultan, Mohammed S ^a   Bawazir, Saleh A ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Saudi Food and Drug Authority   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTINUING EDUCATION; DESCRIPTIVE RESEARCH; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITAL PHARMACY; HUMAN; KNOWLEDGE; MALE; MANDATORY REPORTING; PHARMACIST; PHARMACIST ATTITUDE; PUBLICATION; QUESTIONNAIRE; RESPONSIBILITY; SAUDI ARABIA;

EID: 61849143954     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006 May;26(5):601-608.
2. Committee on Quality of Health Care in America: Institute of Medicine. To err is human: building a safer health system. Washington, D.C.: National Academy Press; 2000
3. Patel H, D Bell, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol. 2007; 7(1):9
4. Pirmohamed M, Breckenridge A, Kitteringham N, Park BK. Adverse drug reactions. Br Med J 1998; 316: 1295-98.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998; 279: 1200-05.
6. Hallas J. Drug-related hospital admission in subspecialites of internal medicine. Dan Med Bull 1996; 43: 141-55.
7. Mannesse CK, Derkx FHM, Ridder M, Man in't Veld A, van der Cammen T. Adverse drug reactions in elderly patients as contributing factors for hospital admission: cross-sectional study. Br Med J 1997; 315: 1057-58.
8. Schneeweiss S, Hasford J, Gottelr M, Hoffman A, Riethling A-K, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospital: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58: 285-91.
9. LA van den Bemt PM, Egberts ACG, Lenderink AW, Simons KA, van der Pol WSC, Leufkens HGM. Adverse drug events in hospitalized patients. Eur J Clin Pharmacol 1999; 55: 155-58.
10. Dormann H, Muth-Selbach U, Krebs S, Criegee-Rick M, Tegeder I, Schneider H T, Hahn E G, Levy M, Brune K, Geisslinger G. Incidence and cost of adverse drug reactions during hospitalisation: Computerised Monitoring Versus Stimulated Spontaneous Reporting. Drug Safe 2000; 22(2): 161-68.
11. Pouyanne P, Haramburu F, Imbs JL, Be'ugard B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. Br Med J 2000; 320: 1036.
12. Mjorndal T, Danell Boman M, Hagg S, et al. Adverse drug reactions as a cause for admission to a department of internal medicine. Pharmacoepidemiol Drug Safe 2000; 11: 65-72.
13. Editorial. Improving ADR reporting. Lancet 2002; 360: 1435.
14. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991; 84: 341-44.
15. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995; 29: 41-49.
16. Chyka PA. How many deaths occur annually from adverse drug reactions in the United States? Am J Med 2000; 109: 122-30.
17. Backstrom M, Mjorndal T, Dahlqvist R, Nordkvist-Olsson T. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol 2000; 56(9-10): 729-32.
18. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. BR J Clin Pharmacol 1995; 39(3): 223-26.
19. Belton KJ, The European Pharmacovigilance Research Group. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997; 52(6): 423-27.
20. Hasford J, Goettler M, Munter KH, Muller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55(9): 945-50.
21. Koch-Weser J, Sidel VW, Sweet RH, Kanarek P, Eaton AE. Factors determining physicians reporting of adverse drug reactions. NEJM 1969; 280: 20-26.
22. Qing L, Zhang SM, Chen HT, Fang SP, Yu X, Liu D. Awareness and attitudes of healthcare professional in Wuhan, China to the reporting of adverse drug reactions. Chin Med J 2004; 116(6): 856-61.
23. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacol Res 1997; 35(2): 85-88.
24. Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48(4): 623-27.
25. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes and behaviour related to reporting adverse drug events. Arch Intern Med 1988; 148: 1596-1600.
26. Bateman DN, Sanders GL, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 1992; 34(5): 421-26.
27. Perlik F, Slanar O, Smid M, Petracek J. Attitude of Czech physicians to adverse drug reaction reporting. Eur J Clin Pharmacol 2002; 58(5): 367-69.
28. Davis S, Coulson R. Community pharmacist reporting of suspected ADRs: (1) The first year of the yellow card demonstration scheme. Pharm J 1999; 263: 786-88.
29. Grootheest K van, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Safety 2004; 13: 457-64.
30. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M. Reporting of adverse drug reactions by nurses. Lancet 2003; 361:1347-48.
31. Grootheest AC van, Passier JL, van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year. Ned Tijdschr Geneeskd 2005; 149: 529-33.
32. Lee KK, Chan TY, Raymon K, Critchley JA. Pharmacists' attitudes toward adverse drug reaction reporting in Hong Kong. Ann Pharmacother 1994; 28: 1400-03.
33. Generali JA, Danish MA, Rosenbaum SE. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists. Ann Pharmacother 1995; 29: 365-69.
34. Ball D, Tisocki T. Adverse drug reporting by general medical practitioners and retail pharmacists in Harare- a pilot study. Cent Aft J Med 1998; 44: 190-95.
35. Houghton J, Wood F, Davis S, Coulson R, Routledge P. Community pharmacist reporting of suspected ADRs: (2) Attitude of community pharmacists and general practitioners in Wales. Pharm J 1999; 263: 788-91.
36. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol 2001; 51: 81-86.
37. Grootheest AC van, Mes K, de Jong-van den Berg LTW. Attitudes of community pharmacists in the Netherlands towards adverse drug reaction reporting. Int J Pharm Pract 2002; 10: 267-72.
38. Bawazir SA. Attitudes of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi pharm j 2006; 14(1): 75-83.
39. Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf 2000; 23:165-7
40. Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci 2008 Oct;30(5):556-62. Epub 2008 Mar 19.
41. Granas AG, Buajordet M, Stenberg-Nilsen H, Harg P, Horn AM. Pharmacists' attitudes towards the reporting of suspected adverse drug reactions in Norway. Pharmacoepidemiology and Drug Safety 2007; 16: 429-34.
42. Williams D, Freely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sc 1999; 168: 257-61.
43. Green CF, Mottram DR, Raval D, Proudlove C, Randall C. Community pharmacists' attitude to adverse drug reaction reporting. Int J Pharm Pract 1999; 7:92-99.
44. Backstrom M, Mjorndal T, Dahlqvist R, Nordkvist-Olsson T. Attitudes to reporting adverse drug reactions in northern Sewden. Eur J Clin Pharmacol 2000; 56: 729-32.
45. Grootheest K van, Oosterhuis I, Puijenbroek EP van, Jong-van den Berg LTW. Underreporting in the spontaneous reporting of adverse drug reactions - a pharmacovigilance approach. In: improving pharmacovigilance and the role of the pharmacist. Grootheest AC van, editor. 2003: 65-79.
46. Vallano A, Cereza G, Pedròs C, Agustí A, Danés I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005 Dec;60(6):653-60.
47. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional. Journal of Evaluation in Clinical Practice 2004; 10: 483-89.
48. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag. 2005 Sep;1(3):181-88.